Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 2/3 3Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 161Breast Neoplasms 125Neoplasm Metastasis 105Melanoma 94Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 69Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 55Pancreatic Neoplasms 51Lung Neoplasms 49Glioblastoma 39Carcinoma, Renal Cell 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Leukemia 36Advanced Solid Tumors 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

xentuzumab 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has results × Prostatic Neoplasms, Castration-Resistant × Clear all
NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed
120 enrolled 28 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡